Information Provided By:
Fly News Breaks for February 26, 2020
BMRN
Feb 26, 2020 | 20:42 EDT
Piper Sandler analyst Christopher Raymond keeps her Overweight rating and $120 price target on BioMarin after its Q4 earnings beat, saying the company's earnings call suggests that it is "firing on all cylinders". Given the implied meaningful growth projected for FY20 and the intermediate-stage pipeline updates on the horizon, the analyst expects the stock to break out of its 3-year rangebound pattern.